QTc prolongation, torsades de pointes, and psychotropic medications.
about
International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxietyAntipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT IntervalImplementation of warnings from Dear Doctor Letters (Rote-Hand-Briefe): an analysis of medication data from a large cohort of elderly patientsEvaluation of Changes in Citalopram Prescribing Patterns Following a US Food and Drug Administration Alert: A Retrospective Cohort Study.Presence or Absence of QTc Prolongation in Buprenorphine-Naloxone Among Youth With Opioid Dependence.Unintentional drowning: Role of medicinal drugs and alcoholQuetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports.Pharmacological treatment for generalized anxiety disorder in adults: an update.The evaluation of thioridazine as a hematopoietic progenitor cell mobilizing agent in healthy human subjectsComputational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.QTc Prolongation in Veterans With Heroin Dependence on Methadone Maintenance Treatment.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.QT prolongation and torsades de pointes with psychotropic agentsAntipsychotic Medication and QT Prolongation.Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.Electrocardiographic abnormalities as potential contributors to premature mortality in patients with mental illness in a psychiatric day treatment programZiprasidone as a Potential Abortive Therapy for Status Migrainosus.QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics.Influence of different second generation antipsychotics on the QTc interval: A pragmatic study.Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.Pharmacological management of depression in patients with cancer: practical considerations.Sertindole in schizophrenia: efficacy and safety issues.CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials.Continuation Rate of Atypical Antipsychotics After Discharge When Initiated in the Intensive Care Unit.Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action.Anxiety Disorders and Cardiovascular Disease.Risk factors for QTc-prolongation: systematic review of the evidence.First-generation antipsychotics and QTc: any role for mediating variables?Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study.High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol.Extreme doses of intravenous methadone for severe pain in two children with cancer.High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia.Lithium Intoxication: A Possible Interaction with Moxifloxacin.Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial.Potential drug-drug interactions and polypharmacy in institutionalized elderly patients in a public hospital in Brazil.Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.
P2860
Q26785374-DAC81A81-4CE0-4A04-96AE-18CBDAC2FE10Q28553078-A8BB75DC-4A88-47D4-BBA8-DEB0BCCF5317Q30810766-09690FF1-34BC-4097-9469-20E801E4F629Q33165968-18D4868D-4696-444C-AFA7-C5625EADC030Q33166593-74646F55-8766-4F5A-8895-A51E71F01146Q33706291-06D90F7B-0B38-4D7D-A981-BDF81CCC81D7Q33937334-C5D05700-FA0F-49DD-A580-1948E3298D10Q34484276-A9A1211A-3DB0-4ED0-BDC2-E4D4CA37B856Q35570535-647939B9-D0C0-42C3-A956-50962F5D7EECQ35646205-441AE9E1-78B9-4692-8580-2A12758D4385Q35729691-59DCE7D4-B6CE-479F-87EC-A4070F1C7D53Q35754726-D1742610-5736-4846-98BD-79B5B9A7A7B5Q35862776-DF8FE168-8489-4C4D-9A12-F18C48C0A63DQ36216816-0B1A5A06-589A-4673-B911-14738099796EQ36270220-315805CC-05F9-42ED-8FD9-5D8CDCF61230Q36403127-C079F171-7394-41AC-9625-3DBC1C214210Q37226992-83208392-35BE-47C9-AA39-D921D7561909Q37268763-7172D457-CF5C-45EC-83BF-7A569865F2B8Q37486960-BB96643C-BBE8-4FF4-829B-98BCDC947CA1Q37532019-87DB398B-A4DC-4B0B-A362-6F0990102EA0Q37596135-9A055699-87EE-4C2E-BE0F-A63C2185A5EBQ38120495-5C5CB898-5F77-439B-99D9-B27E56A9F5C2Q38236032-226450A6-B928-48ED-98CD-259084725185Q38239777-279FF86D-98A4-4CF9-98E9-F2F4AE040C42Q38304559-369C012F-6979-4753-BEC5-4604EE9191DDQ38821189-F2A6C246-AE7A-42D0-9C6E-FC3AB8D4D6CFQ38872058-7A12F834-6E7C-4DEF-B923-8E00BC45F607Q38965295-E620AC6F-1822-4D56-B56E-FB25B4DF1362Q39052301-6D245439-10CF-4502-83C2-6B490B60C236Q39721569-4A62ECB6-0CCB-4F90-8728-610E76ADCB45Q40125010-CB5A0855-E1A6-4B2C-A438-6D66DE7CD39FQ40431985-58054268-B330-49D2-A55A-F4780B10608BQ40543775-3B1E9503-328F-484C-8EBA-3A64737B9A4EQ40900114-418E429B-11B3-440A-8A6D-A6ED1063A601Q41495525-777B38EA-5076-490D-8B28-F2D7C7E9ECA2Q42382868-BB451D35-A747-4C54-AC62-E4159BDC7686Q47138846-B065E673-82EE-4D38-9790-8D16310156B1Q47569717-2E1D3464-85D4-483A-BE41-8DB2EF6F36E2Q47624955-6F8063D6-ED21-4A2A-BA9D-C0F45EFCDA05Q47643184-95CB2DA2-9A7F-435A-8D30-99C623011704
P2860
QTc prolongation, torsades de pointes, and psychotropic medications.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
QTc prolongation, torsades de pointes, and psychotropic medications.
@ast
QTc prolongation, torsades de pointes, and psychotropic medications.
@en
QTc prolongation, torsades de pointes, and psychotropic medications.
@nl
type
label
QTc prolongation, torsades de pointes, and psychotropic medications.
@ast
QTc prolongation, torsades de pointes, and psychotropic medications.
@en
QTc prolongation, torsades de pointes, and psychotropic medications.
@nl
prefLabel
QTc prolongation, torsades de pointes, and psychotropic medications.
@ast
QTc prolongation, torsades de pointes, and psychotropic medications.
@en
QTc prolongation, torsades de pointes, and psychotropic medications.
@nl
P2093
P1433
P1476
QTc prolongation, torsades de pointes, and psychotropic medications.
@en
P2093
Christopher M Celano
Jeff C Huffman
Peter A Noseworthy
Scott R Beach
P356
10.1016/J.PSYM.2012.11.001
P577
2013-01-01T00:00:00Z